RGRX (Regenerx Biopharmaceuticals) ROC %: -153.65% (As of Mar. 2023)


What is Regenerx Biopharmaceuticals ROC %?

Regenerx Biopharmaceuticals RGRX ROC % is -153.65% as of Mar. 2023.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Regenerx Biopharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Mar. 2023 was -153.65%.

As of today (2026-07-04), Regenerx Biopharmaceuticals's WACC % is 0.00%. Regenerx Biopharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Regenerx Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Regenerx Biopharmaceuticals  (OTCPK:RGRX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Regenerx Biopharmaceuticals's WACC % is 0.00%. Regenerx Biopharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Regenerx Biopharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Regenerx Biopharmaceuticals ROC % Related Terms


Regenerx Biopharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals ROC % Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -127.76 -781.42 -641.09 -642.03 -717.14

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,004.38 -1,805.83 -802.83 -583.02 -153.65

Regenerx Biopharmaceuticals ROC % Calculation

Regenerx Biopharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-1.402 * ( 1 - 0% )/( (0.159 + 0.232)/ 2 )
=-1.402/0.1955
=-717.14 %

where

Regenerx Biopharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2023 is calculated as:

ROC % (Q: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Mar. 2023 ))/ count )
=-1.22 * ( 1 - 0% )/( (0.232 + 1.356)/ 2 )
=-1.22/0.794
=-153.65 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -153.65% mean?
Regenerx Biopharmaceuticals (RGRX) has a ROC % of -153.65% as of Mar. 2023. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' ROC % too high?
Regenerx Biopharmaceuticals' current ROC % is -153.65%.
How does Regenerx Biopharmaceuticals' ROC % compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' ROC % of -153.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Regenerx Biopharmaceuticals and its competitors. Regenerx Biopharmaceuticals's current ROC % is -153.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current ROC % of -153.65%. The current ROC % is -153.65%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current ROC % is -153.65% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.